Study drug
depression
In the induction phase, participants self-administered (under medical supervision) esketamine (28 mg [starting dose age ≥65 years], 56 mg, or 84 mg) as a flexible dose, twice-weekly therapy for 4 weeks. In the optimization/maintenance phase, participants received interval dosing of esketamine individualized to the severity of their depression based upon a clinical global impression - severity [CGI-S]-based algorithm (refer to Table Throughout the study, esketamine was dispensed only at clinical sites during each dosing session and dose administration occurred under direct supervision of site staff.